Human papilloma virions in the laboratory

Journal of Clinical Virology

Volumn 61, Issue 2, 2014, Pages 196-198

  Dunne, Eileen F ^a   Markowitz, Lauri E ^a   Taylor, La'shan D ^a,b   Unger, Elizabeth R ^c   Wheeler, Cosette M ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

HPV; HPV vaccines; Human papillomavirus; Laboratory safety

Indexed keywords

WART VIRUS VACCINE;

HUMAN; INFECTION RISK; LABORATORY; LABORATORY PERSONNEL; NONHUMAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRION; WART VIRUS; WILD TYPE; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; OCCUPATIONAL DISEASES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; VIROLOGY;

HUMANS; LABORATORIES; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84924048842     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.06.014     Document Type: Review

References (25)

1. Buck C.B., Pastrana D.V., Lowy D.R., Schiller J.T. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 2005, 119:445-462.
2. Buck C.B., Thompson C.D. Production of papillomavirus-based gene transfer. Current Protocols in Cell Biology 2007, 26:1-26.
3. Castellsague X., Munoz N., Pitisuttithum P., Ferris D., Monsonego J., Ault K., et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011, 105:28-37.
4. CDC FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010, 59(20):626-629.
5. CDC Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP). MMWR 2011, 60(50):1705-1708.
6. CDC. Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition accessed October 28, 2013:. http://www.cdc.gov/biosafety/publications/bmbl5/.
7. Chow L.T., Duffy A.A., Wang H.K., Broker T.R. A highly efficient system to produce infectious human papillomavirus. Cell Cycle 2009, 8:1319-1323.
8. Culp T.D., Cladel N.M., Balogh K.K., Budgeon L.R., Mejia A.F., Christensen N.D. Papillomavirus particles assembled in 293TT cells are infectious in vivo. J Virol 2006, 80:11381-11384.
9. Fang L., Meyers C., Budgeon L.R., Howett M.K. Induction of productive human papillomavirus type 11 life cycle in epithelial cells grown in organotypic raft cultures. Virology 2006, 347:28-35.
10. Ferenczy A., Bergeron C., Richart R.M. Human papillomavirus DNA in fomites on objects used for the management of patients with genital human papillomavirus infections. Obstet Gynecol 1989, 74(6):950-954.
11. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med 2007, 356(19):1928-1943.
12. Grant L.A., Dunne E.F., Chesson H., Markowitz L.E. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States. Vaccine 2011, 29:2635-2670.
13. Herrero R., Quint W., Hildesheim A., et al. CVT Vaccine Group. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013, 8(July (7)):e68329.
14. Hildesheim A., Herrero R., Wacholder S., et al. Vaccine trial group. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007, 298(7):743-753.
15. Howley Peter M., Lowy Douglas R. Papillomaviruses. Fields Virology 2007, 2299-2354. Lippincott Williams and Wilkins, Philadelphia. 5th ed. M. Knipe David, Howley, M. Peter (Eds.).
16. McCance D., Kopan R., Fuchs E., et al. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc. Natl. Acad. Sci. 1988, 85:7169-7173.
17. McLaughlin-Drubin M.E., Wilson S., Mullikin B., Suzich J., Meyers C. Human papillomavirus type 45 propagation, infection, and neutralization. Virology 2003, 312:1-7.
18. McLaughlin-Drubin M.E., Meyers C. Evidence for the coexistence of two genital tHPV types within the same host cell in vitro. Virology 2004, 321(2):173-180.
19. Meyers C., Mayer T.J., Ozbun M.A. Synthesis of infection human papillomavirus type 18 in differentiated epithelium transfected with viral DNA. J Virol 1997, 71(10):7381-7386.
20. Meyers J., Ryndock E., Conway J.J., Meyers C., Robison R. Susceptibility of high-risk human papillomavirus type 16 to clinical disinfectants. J Anitmicrob Chemother 2014, 69:1546-1550.
21. Munoz N., Manalastas R., Pitisuttithum P., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373(9679):1949-1957.
22. Ozbun M.A. Infectious human papillomavirus type 31b: purification and infection of an immortalized human keratinocyte cell line. J Gen Virol 2002, 83:2753-2763.
23. Pyeon D., Lambert P.F., Ahlquist P. Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc Natl Acad Sci U S A 2005, 102:9311-9316.
24. Roden R.B., Lowy D.R., Schiller J.T. Papillomavirus is resistant to desiccation. J Infect Dis 1997, 176(4):1076-1079.
25. Song H., Moseley P.L., Lowe S.L., Ozbun M.A. Inducible heat shock protein 70 enhances HPV31 viral genome replication and virion production during the differentiation-dependent life cycle in human keratinocytes. Virus Res 2010, 147:113-122.